Hazard identification of dangerous goods

For long, a lot of accidents related to goods transportation proved the need of hazards identification. International regulations are in existence for air, ground (road, rail), sea and waterways transportation. For about 25 years, a committee of experts has been dealing at United Nations level on Transportation of Dangerous Goods (TDG) and recently (beginning 2001) extended its work to Globally Harmonized System of Classification and Labelling for Chemicals. In this lecture, will be presented first some typical accidents occurred with different types of goods : explosives, flammable substances (sinking of Ievoli Sun transporting chemicals and Erika transporting oil), toxic and corrosive, unclassified goods (Channel Tunnel in 1995, Mont-Blanc and Tauern tunnels in 1999). Then, a brief description of international regulations and of dangerous goods will be presented. Comments will be given on classification methods and procedures

Evaluation des produits émis lors d'incendies accidentels de substances dangereuses

International audienceL'evaluation de l'inflammabilite, l'explosibilite et la toxicite de substances dangereuses peut conduire à un classement. Diverses methodes de laboratoire sont utilisees et retenues dans des normes et reglementations, nationales et internationales. Les methodes indiquees dans les recommandations de l'ONU pour le transport des matieres dangereuses et les Directives de la Commission Economique Europeenne (84/449 et 82/501) sont d'abord examinees. Sur l'aspect de l'emission de produits toxiques lors d'incendies accidentels, divers sinistres importants mettant en jeu des engrais ou des produits phytosanitaires ont montre les limitations de l'evaluation basee sur des methodes de laboratoire. Par contre, des essais en grand dans une galerie d' incendie de 50 m de long et 10 m2 de section ont permis d'effectuer des bilans massiques et chimiques globaux de l'incendie d'engrais ternaires NPK et de produits agropharmaceutiques, et d'evaluer les impacts thermiques. Ces travaux ont mis en evidence les differences de comportement dans la combustion des produits ä l'echelle du laboratoire et en grand, et le rôle de leur conditionnement

Landscape design for soil conservation under land use and climate change

International audienceSoils and landscapes evolve simultaneously. Soil evolution is controlled by redistribution and transformation processes influenced by topographic and climatic parameters, with also a major contribution of management strategies. The perennial landscape features have a strong influence on soil spatial distribution (geometry) and soil genesis. Building landscapes which enhance soil resilience to degradation processes and increase soil services appears as a promising way to adapt to forthcoming climatic and land use evolutions. The presentation aims to synthetize major results from a research program nicknamed Landsoil which focused on the evolution of agricultural soils over medium time scales (decades to centuries) in relation to changing conditions of land use and climate. Precise study of the soil 3D organization in three contrasted landscapes (Brittany, Touraine, Languedoc-Roussillon) enabled to link soil redistribution in space to landscape components (field geometry, hedges or ditches network) and their past evolution. A dynamic and high resolution spatial modeling approach was developed coupling erosion processes and soil organic matter evolution and was calibrated over past evolution using dating techniques (Cs137, C14, OSL). The resulting Landsoil model was afterwards applied in a prospective manner under different scenarios of land use and climate change over the 21th century. Indicators of soil vulnerability and soil resilience were defined and tested by the comparison of several prospective scenarios applied on a same landscape and by comparison of the contrasted landscapes

Inhibition of Chondrosarcoma Growth by mTOR Inhibitor in an In Vivo Syngeneic Rat Model

BACKGROUND: Chondrosarcomas are the second most frequent primary malignant type of bone tumor. No effective systemic treatment has been identified in advanced or adjuvant phases for chondrosarcoma. The aim of the present study was to determine the antitumor effects of doxorubicin and everolimus, an mTOR inhibitor on chondrosarcoma progression. METHODS AND FINDINGS: Doxorubin and/or everolimus were tested in vivo as single agent or in combination in the rat orthotopic Schwarm chondrosarcoma model, in macroscopic phase, as well as with microscopic residual disease. Response to everolimus and/or doxorubicin was evaluated using chondrosarcoma volume evolution (MRI). Histological response was evaluated with % of tumor necrosis, tumor proliferation index, metabolism quantification analysis between the treated and control groups. Statistical analyses were performed using chi square, Fishers exact test. Doxorubicin single agent has no effect of tumor growth as compared to no treatment; conversely, everolimus single agent significantly inhibited tumor progression in macroscopic tumors with no synergistic additive effect with doxorubicin. Everolimus inhibited chondrosarcoma proliferation as evaluated by Ki67 expression did not induce the apoptosis of tumor cells; everolimus reduced Glut1 and 4EBP1 expression. Importantly when given in rats with microscopic residual diseases, in a pseudo neoadjuvant setting, following R1 resection of the implanted tumor, everolimus significantly delayed or prevented tumor recurrence. CONCLUSIONS: MTOR inhibitor everolimus blocks cell proliferation, Glut1 expression and HIF1a expression, and prevents in vivo chondrosarcoma tumor progression in both macroscopic and in adjuvant phase post R1 resection. Taken together, our preclinical data indicate that mTOR inhibitor may be effective as a single agent in treating chondrosarcoma patients. A clinical trial evaluating mTOr inhibitor as neo-adjuvant and adjuvant therapy in chondrosarcoma patients is being constructed

Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray

Metastatic colorectal carcinomas (CRC) resistant to chemotherapy may benefit from targeting monoclonal therapy cetuximab when they express the epidermal growth factor receptor (EGFR). Because of its clinical implications, we studied EGFR expression by immunohistochemistry on tissue sections of primary CRC (n=32) and their related metastases (n=53). A tissue microarray (TMA) was generated from the same paraffin blocks to determine whether this technique could be used for EGFR screening in CRC. On tissue sections, 84% of the primary CRC and 94% of the metastases were EGFR-positive. When matched, they showed a concordant EGFR-positive status in 78% of the cases. Moreover, staining intensity and extent of EGFR-positive cells in the primary CRC correlated with those observed in the synchronous metastases. On TMA, 65% of the primary CRC, 66% of the metastases, and 43% of the matched primary CRC metastases were EGFR-positive. There was no concordant EGFR status between the primary and the metastatic sites. A strong discrepancy of EGFR status was noted between TMA and tissue sections. In conclusion, EGFR expression measured in tissue sections from primary CRC and their related metastases was found to be similar and frequent, but it was significantly underestimated by the TMA technique

BMJ Med

OBJECTIVE: To evaluate the efficacy of covid-19 convalescent plasma to treat patients admitted to hospital for moderate covid-19 disease with or without underlying immunodeficiency (CORIPLASM trial). DESIGN: Open label, randomised clinical trial. SETTING: CORIMUNO-19 cohort (publicly supported platform of open label, randomised controlled trials of immune modulatory drugs in patients admitted to hospital with moderate or severe covid-19 disease) based on 19 university and general hospitals across France, from 16 April 2020 to 21 April 2021. PARTICIPANTS: 120 adults (n=60 in the covid-19 convalescent plasma group, n=60 in the usual care group) admitted to hospital with a positive SARS-CoV2 test result, duration of symptoms 40. MAIN OUTCOME MEASURES: Primary outcomes were proportion of patients with a WHO Clinical Progression Scale score of ≥6 on the 10 point scale on day 4 (higher values indicate a worse outcome), and survival without assisted ventilation or additional immunomodulatory treatment by day 14. Secondary outcomes were changes in WHO Clinical Progression Scale scores, overall survival, time to discharge, and time to end of dependence on oxygen supply. Predefined subgroups analyses included immunosuppression status, duration of symptoms before randomisation, and use of steroids. RESULTS: 120 patients were recruited and assigned to covid-19 convalescent plasma (n=60) or usual care (n=60), including 22 (covid-19 convalescent plasma) and 27 (usual care) patients who were immunocompromised. 13 (22%) patients who received convalescent plasma had a WHO Clinical Progression Scale score of ≥6 at day 4 versus eight (13%) patients who received usual care (adjusted odds ratio 1.88, 95% credible interval 0.71 to 5.24). By day 14, 19 (31.6%) patients in the convalescent plasma group and 20 (33.3%) patients in the usual care group needed ventilation, additional immunomodulatory treatment, or had died. For cumulative incidence of death, three (5%) patients in the convalescent plasma group and eight (13%) in the usual care group died by day 14 (adjusted hazard ratio 0.40, 95% confidence interval 0.10 to 1.53), and seven (12%) patients in the convalescent plasma group and 12 (20%) in the usual care group by day 28 (adjusted hazard ratio 0.51, 0.20 to 1.32). In a subgroup analysis performed in patients who were immunocompromised, transfusion of covid-19 convalescent plasma was associated with mortality (hazard ratio 0.39, 95% confidence interval 0.14 to 1.10). CONCLUSIONS: In this study, covid-19 convalescent plasma did not improve early outcomes in patients with moderate covid-19 disease. The efficacy of convalescent plasma in patients who are immunocompromised should be investigated further. TRIAL REGISTRATION: ClinicalTrials.gov NCT04345991

INERIS action in the field of dangerous substances

International audienceSince it was created in 1947. the Centre d'Etudes et Recherches de Charbonnages de France (CERCHAR) has devoted a considerable part of its activity to safety with regard to explosion risks in the Underground workings of coal mines. It has been concerned with the use of explosive products in these workings, the main aim being to reduce the risk of firedamp and coal dust ignition. For about twenty years, the work relating to explosive products has gradually included, on the one hand, their use in mines other than coal mines and in quarries and, on the other hand, the general safety (manufacture, transport, storage and use) of explosive products as a whole designed for civll use. In the same period, the work on gas and dust explosions has been extended to the majority of industries : chemical, petrochemical and the agricultural industr

La formation universitaire aux métiers du sport et de l’éducation physique en Bretagne : acteurs et territoires (1965-2015)

International audienc

La fibromyalgie (étude descriptive et comparative de la qualité de vie et de facteurs psychiatriques)

MONTPELLIER-BU Médecine UPM (341722108) / SudocPARIS-BIUM (751062103) / SudocMONTPELLIER-BU Médecine (341722104) / SudocSudocFranceF